Relief Therapeutics Holding Stock Performance
| RLFTF Stock | USD 4.27 0.08 1.91% |
The company holds a Beta of 0.54, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Relief Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Relief Therapeutics is expected to be smaller as well. At this point, Relief Therapeutics has a negative expected return of -0.65%. Please make sure to check Relief Therapeutics' potential upside, as well as the relationship between the daily balance of power and market facilitation index , to decide if Relief Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Relief Therapeutics Holding has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 43.2 M | |
| Total Cashflows From Investing Activities | -30.3 M |
Relief |
Relief Therapeutics Relative Risk vs. Return Landscape
If you would invest 707.00 in Relief Therapeutics Holding on October 21, 2024 and sell it today you would lose (280.00) from holding Relief Therapeutics Holding or give up 39.6% of portfolio value over 90 days. Relief Therapeutics Holding is currently producing negative expected returns and takes up 5.464% volatility of returns over 90 trading days. Put another way, 48% of traded otc stocks are less volatile than Relief, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Relief Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Relief Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Relief Therapeutics Holding, and traders can use it to determine the average amount a Relief Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1183
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RLFTF |
Estimated Market Risk
| 5.46 actual daily | 48 52% of assets are more volatile |
Expected Return
| -0.65 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Relief Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Relief Therapeutics by adding Relief Therapeutics to a well-diversified portfolio.
Relief Therapeutics Fundamentals Growth
Relief OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Relief Therapeutics, and Relief Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Relief OTC Stock performance.
| Return On Equity | -0.33 | |||
| Return On Asset | -0.12 | |||
| Operating Margin | (5.96) % | |||
| Current Valuation | 102.36 M | |||
| Shares Outstanding | 4.39 B | |||
| Price To Book | 0.70 X | |||
| Price To Sales | 22.16 X | |||
| Revenue | 3.32 M | |||
| EBITDA | (33.3 M) | |||
| Cash And Equivalents | 29.87 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 396 K | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (35.72 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 251.62 M | |||
About Relief Therapeutics Performance
By analyzing Relief Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Relief Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Relief Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Relief Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company was founded in 2013 and is based in Geneva, Switzerland. Mondobiotech Holding is traded on OTC Exchange in the United States.Things to note about Relief Therapeutics performance evaluation
Checking the ongoing alerts about Relief Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Relief Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Relief Therapeutics generated a negative expected return over the last 90 days | |
| Relief Therapeutics has high historical volatility and very poor performance | |
| Relief Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 3.32 M. Net Loss for the year was (34.7 M) with profit before overhead, payroll, taxes, and interest of 2.57 M. | |
| Relief Therapeutics Holding has accumulated about 29.87 M in cash with (35.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
- Analyzing Relief Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Relief Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Relief Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Relief Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Relief Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Relief Therapeutics' otc stock. These opinions can provide insight into Relief Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Relief OTC Stock analysis
When running Relief Therapeutics' price analysis, check to measure Relief Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relief Therapeutics is operating at the current time. Most of Relief Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relief Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relief Therapeutics' price. Additionally, you may evaluate how the addition of Relief Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |